Stanley Druckenmiller’s Vaxcyte Inc (PCVX) position
Reported position history, portfolio importance and verified filing changes from public SEC disclosures.
At a glance
The full verified relationship, including prior ownership episodes and exits where supported.
Duquesne Family Office first reported Vaxcyte Inc in Q3 2024. The reported position was increased across later filings. The latest verified relationship event shows that Duquesne Family Office sold the entire position in Q1 2025, and the stock is no longer reported in the latest verified portfolio.
Position over time
See the same verified relationship through reported shares, portfolio weight or reported value.
Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.
What changed
Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.
Filing context
Quarter-end price $81.86 · Estimated holding basis $98.01
Filing context
Quarter-end price $114.28 · Estimated holding basis $114.28
How important was Vaxcyte Inc in Duquesne Family Office’s reported portfolio?
Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.
Who else owns Vaxcyte Inc?
Also reported by 1 other tracked investor in their latest verified filings.
SEC filing evidence
Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.
Market context only; not an investor transaction price.
This tracker follows Duquesne Family Office LLC’s Form 13F disclosures—not Stanley Druckenmiller’s personal brokerage account. Form 13F reports quarter-end U.S.-listed positions and certain options, but it does not reveal exact trade dates, execution prices, short positions or the purpose of an option position.